Comparative Pharmacology
Head-to-head clinical analysis: FAMVIR versus LIVTENCITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMVIR versus LIVTENCITY.
FAMVIR vs LIVTENCITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famciclovir is a prodrug that is rapidly converted to penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thereby inhibiting viral DNA synthesis and replication.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
250 mg orally three times daily for 7 days for herpes zoster; 125 mg orally twice daily for 5 days for recurrent genital herpes; 250 mg orally twice daily for 7 days for first-episode genital herpes; 500 mg orally twice daily for 7 days for herpes zoster in immunocompromised patients; 500 mg orally twice daily for 7 days for recurrent mucocutaneous herpes in HIV patients.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life of penciclovir is approximately 2–3 hours in patients with normal renal function; extends to 9–18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Renal: 60–70% as penciclovir via tubular secretion and glomerular filtration; fecal: <10%; biliary: <1%.
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Category C
Category C
Antiviral
Antiviral